Health · Pharma & Biotech · 2 days ago
Argenx’s Vyvgart fails to outperform placebo in Sjögren’s disease trial
Argenx tested its drug Vyvgart in people with Sjögren’s disease, a chronic autoimmune disorder.
The drug did not work better than a placebo in the Phase 3 trial.
The study was stopped early because a monitoring committee decided it would not meet its main goal.
The result is a setback for Argenx, which has had success with other autoimmune diseases.
Argenx said Vyvgart failed to outperform placebo in a Phase 3 trial involving patients with Sjögren’s disease.
A data monitoring committee determined that the trial would not meet its primary endpoint, and the study was stopped early.
The trial had been expected to be completed next year.
William Blair analysts had projected peak sales of $1.4 billion for Vyvgart in Sjögren’s disease, while describing the trial as high risk.
- Who
- Argenx and patients with Sjögren’s disease.
- What
- Vyvgart failed to outperform placebo in a Phase 3 trial, which was stopped early.
- When
- The article was published on October 9, 2026. The trial had been expected to finish next year.
- Where
- Not stated.
- Why
- A data monitoring committee determined the trial would not meet its primary endpoint. The article says Sjögren’s patients often have high placebo responses.
This story does not have two clearly opposing sides.
No direct quotes in the coverage so far.
The study was expected to be completed next year.
The committee determined the primary endpoint would not be met, and the trial was stopped early.
- Drug
- Vyvgart
- Trial phase
- Phase 3
- Condition
- Sjögren’s disease, a chronic autoimmune disorder
- Trial outcome
- Failed to outperform placebo
- Projected peak sales
- $1.4 billion in Sjögren’s disease according to William Blair analysts
Sources
Related news
Pilot trial tests support to limit weight regain after GLP-1 drugs stop
Dong-A launches three ibuprofen-based cold medicines
FDA approves atezolizumab with chemotherapy for some stage III colon cancers
Review links drug company gifts to more and less appropriate prescribing
Brazil suspends Peptistrong supplement and orders all batches recalled
Experimental injection reduced visceral fat by 12% in early trials
AstraZeneca blames trial design for failed bone disease drug study
Spain withdraws five erectile dysfunction supplements containing undeclared drugs
Baby Sleep Gripe Water Recalled After Alcohol Found in Testing
FDA Warns Amazon Over Unapproved Herpes Treatments
Possible Wrong Dose Raises Questions for PDE9 Drug Trials in Heart Failure
